EGFR and neoplasm: If the actionable (primary) EGFR mutation is detected, the absence of the T790M mutation is more reliable, while if none of the two mutations is detected, it could be assumed that the tumor is not releasing a sufficient amount of DNA in the bloodstream; thus, liquid biopsy analysis could be more reliable later during treatment [9].